Blood plasma composition plays a critical role in the aging process and the progression of age-related diseases.

From Parabiosis to "Young Blood" The foundation of this field stems from "heterochronic parabiosis" experiments, where the circulatory systems of young and old animals are surgically connected. These studies demonstrated that exposure to a young systemic environment can rejuvenate aged tissues—such as muscle, liver, and brain—while old blood accelerates aging in young animals. This sparked a controversial commercial fad where startups offered "young blood" plasma infusions to older adults. However, the FDA issued strong warnings against this practice, stating that such treatments have no proven clinical benefits for anti-aging and carry significant safety risks, forcing many of these clinics to shut down.

The Paradigm Shift: Plasma Dilution and TPE Recent breakthroughs have shifted the scientific consensus away from needing "young blood" toward the benefits of removing age-elevated, harmful factors present in old blood. Researchers discovered that simply diluting the blood plasma of old mice—replacing half of it with a neutral mixture of saline and albumin—achieves the same or stronger rejuvenating effects as administering young blood.

In humans, this concept is applied through Therapeutic Plasma Exchange (TPE) or plasmapheresis, a clinically established procedure that separates and removes plasma, replacing it with a substitute fluid. TPE acts as a "molecular reset button" by clearing out pro-inflammatory proteins, metabolic waste, and pathogenic autoantibodies that accumulate with age, allowing beneficial, pro-regenerative proteins to rebound.

Clinical Success in Alzheimer's and Biological Aging TPE is showing immense promise in clinical settings:

• Alzheimer’s Disease (The AMBAR Trial): A landmark clinical trial demonstrated that treating mild-to-moderate Alzheimer's patients with TPE and albumin replacement significantly slowed cognitive and functional decline (by 52% to 66%). The procedure removes toxic amyloid-beta proteins and inflammatory mediators from the blood, which encourages their clearance from the brain.
• Reducing Biological Age: A recent human trial from the Buck Institute showed that repeated TPE treatments significantly reduced patients' epigenetic (biological) age by an average of 1.32 to 2.61 years, while also improving immune profiles and lowering DNA damage.

The Future of Rejuvenation Instead of crude plasma transfusions, modern biotechnology is focusing on targeted approaches. Researchers are identifying specific circulating proteins (like GDF11 or CCL11) and extracellular vesicles (EVs) that actively drive aging or regeneration. Companies are now developing specific plasma fractions and recombinant proteins to treat stroke, cognitive decline, and metabolic diseases. While these therapies hold massive potential for extending the human healthspan, they also raise complex ethical questions regarding the global supply and compensated donation of human plasma.